FORM (by GBY) Review: Four Products, Zero Published Prices

The one-sentence version

FORM by GBY lists a genuine longevity/peptide catalogue under its Peptides/Longevity category — NAD+ Therapies, Sermorelin Injections, GHK-Cu Cream, Glutathione Injections — and publishes a price for none of the four. No floor, no "from" figure, no ladder. It grades C, 4 points out of 14 — tied for the lowest score on this board — computed from published terms alone.

What it is, and who it's for

FORM markets a broad telehealth catalogue spanning GLP-1 weight loss and a separate Peptides/Longevity vertical. The longevity line is real and live: NAD+ Therapies, Sermorelin Injections, GHK-Cu Cream and Glutathione Injections are all listed as products, not teased as coming soon. Both LegitScript and HIPAA compliance badges are displayed, and the site states coverage across 48 states plus DC, excluding Alaska and Mississippi.

The buyer this suits is someone already sold on FORM's brand who is willing to start an intake to find out what any of the four products costs. The buyer it does not suit is anyone trying to comparison-shop from the outside, because there is nothing to compare.

What it actually costs

Verified live on formbygby.com, 4 August 2026. No price is published anywhere for NAD+, sermorelin, GHK-Cu cream, or glutathione injections. We checked the Peptides/Longevity category page and each product listing; none carries a figure. FORM's only published prices belong to its separate GLP-1 line — compounded semaglutide at $299/month, and a $95/month figure that is a membership fee, not a drug cost, and has no bearing on what the longevity products cost.

That gap is the entire case for scoring this row at zero on price transparency. Our rubric asks for one all-in figure, visible before a reader commits — CeliaRx publishes one per fill, Nolu publishes a floor, and FORM publishes nothing at all for the four products this board actually ranks on. Compare the FORM entry itself against Nolu, which at least states a starting number even without a dose breakdown: FORM does not clear that lower bar either.

Clinical oversight and the pharmacy

No medical director, individual prescriber, or compounding pharmacy is named anywhere on formbygby.com for the NAD+, sermorelin, GHK-Cu, or glutathione lines. This board scores an unstated fact as unstated rather than assumed favorable, the same standard applied to every row we grade — so both clinical oversight and pharmacy disclosure score zero here, not because FORM is doing something wrong, but because nothing is published to credit.

The evidence behind what it sells

FORM's marketing does not make cognition-specific claims for its longevity line, and the underlying evidence for the four products it lists is consistent with the rest of this board. The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials and found effects on functional, metabolic and vascular outcomes "heterogeneous and often null or endpoint-specific," with clinical effectiveness inconclusive¹. Sermorelin's own trial record: nightly GHRH 1-29 for six weeks in eleven healthy men aged 64–76 raised nocturnal growth hormone but produced no change in IGF-1 and no change in DEXA-measured muscle or fat². GHK-Cu has a stronger mechanistic and preclinical case for tissue repair than most peptides sold on this board, though human outcome trials remain limited³. See NAD+ for longevity and peptides for longevity.

Where it's weak, and who should skip it

Skip it if you want to know what anything costs before you start an intake — that information does not exist on the public site for any of the four products in this category. If you proceed anyway, get the price for your specific product in writing before submitting payment information, and confirm the state-availability list for the product you want, since FORM's stated exclusions (Alaska, Mississippi) apply to the wider catalogue and may not be product-specific.

The verdict, against the rubric

Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). FORM takes the full four for a genuine, live NAD+/peptide catalogue — the products are real — and zero everywhere else: zero on price transparency, because none of the four carries a published figure; zero on clinical oversight and zero on pharmacy, because neither is named or described anywhere on the site; zero on human support, which is not stated as included. Four of fourteen: a C, tied for the lowest score on this board. Two neighbours added the same day are our EdgeRx review and Nolu review; the full field is at our provider rankings.